{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:35:43Z","timestamp":1773941743771,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s110189","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T03:51:12Z","timestamp":1470628272000},"page":"4843-4858","source":"Crossref","is-referenced-by-count":4,"title":["Salvage therapies in relapsed and\/or refractory myeloma: what is current and what is the future?"],"prefix":"10.2147","volume":"Volume 9","author":[{"given":"Nishitha","family":"Thumallapally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Asti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh","family":"Vennepureddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tering","family":"Terjanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,8]]},"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=31748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T23:00:09Z","timestamp":1477868409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/salvage-therapies-in-relapsed-andor-refractory-myeloma-what-is-current-peer-reviewed-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ott.s110189","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}